<DOC>
	<DOC>NCT02870231</DOC>
	<brief_summary>This trial is conducted in the United States of America. The aim of this trial is to investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the effect of the investigated drug on the body) for Multiple Doses of NNC9204-0530 in Combination with Liraglutide in Male and Female Subjects being Overweight or with Obesity</brief_summary>
	<brief_title>Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Nutrition Disorders</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Body mass index between 25.0 and 39.9 kg/m^2 (both inclusive) at screening. Male or female, age between 18 and 55 years (both inclusive) at the time of signing informed consent Any clinically significant weight change (equal or above 5% selfreported change) or dieting attempts (e.g. participation in an organized weight reduction program within the last 90 days prior to screening Any prior obesity surgery or currently present gastrointestinal implant. Thyroidstimulating hormone (TSH) values outside 0.46.0 mIU/L Glycosylated haemoglobin (HbA1c)above or equal to 6.5% or in Syst√®me International (SI) units 48 mmol/mol Abnormal ECG (electrocardiogram) results including 2nd or 3rd degree AVblock, prolongation of the QRS complex above 120 ms, or the QTcF interval above 430 ms (males) or above 450 ms (females), or other clinically relevant abnormal results, as judged by the investigator A history of additional risk factors for Torsades de pointes (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome) Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) Calcitonin above or equal to 50 ng/L History of pancreatitis (acute or chronic)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>